NESINA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nesina, and what generic alternatives are available?
Nesina is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-nine patent family members in thirty-seven countries.
The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alogliptin benzoate profile page.
DrugPatentWatch® Generic Entry Outlook for Nesina
Nesina was eligible for patent challenges on January 25, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 16, 2029. This may change due to patent challenges or generic licensing.
There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There are two tentative approvals for the generic drug (alogliptin benzoate), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for NESINA
International Patents: | 69 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 14 |
Patent Applications: | 265 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for NESINA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NESINA |
What excipients (inactive ingredients) are in NESINA? | NESINA excipients list |
DailyMed Link: | NESINA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NESINA
Generic Entry Date for NESINA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NESINA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sanofi | Phase 4 |
Takeda Development Center Americas, Inc. | Phase 3 |
Kun-Ho Yoon | Phase 4 |
Pharmacology for NESINA
Drug Class | Dipeptidyl Peptidase 4 Inhibitor |
Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for NESINA
Paragraph IV (Patent) Challenges for NESINA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NESINA | Tablets | alogliptin benzoate | 6.25 mg, 12.5 mg and 25 mg | 022271 | 5 | 2017-01-25 |
US Patents and Regulatory Information for NESINA
NESINA is protected by four US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NESINA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting NESINA
Dipeptidyl peptidase inhibitors
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Dipeptidyl peptidase inhibitors
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
Dipeptidyl peptidase inhibitors
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Tablet preparation without causing a tableting trouble
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting NESINA
REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
Exclusivity Expiration: ⤷ Try a Trial
Expired US Patents for NESINA
EU/EMA Drug Approvals for NESINA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Takeda Pharma A/S | Vipidia | alogliptin benzoate | EMEA/H/C/002182 Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations). |
Authorised | no | no | no | 2013-09-18 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for NESINA
When does loss-of-exclusivity occur for NESINA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 5096
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 77193
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 08000280
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0171518
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 24901
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 84967
Estimated Expiration: ⤷ Try a Trial
Patent: 10517936
Estimated Expiration: ⤷ Try a Trial
Peru
Patent: 081734
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 39854
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 0836774
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering NESINA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 200302126 | ⤷ Try a Trial | |
Taiwan | 200836774 | Solid preparation | ⤷ Try a Trial |
European Patent Office | 2292268 | ⤷ Try a Trial | |
Czech Republic | 291624 | Farmaceutický přípravek (Pharmaceutical composition) | ⤷ Try a Trial |
Argentina | 048055 | DERIVADOS DE PIRIMIDINA COMO INHIBIDORES DE DIPEPTIDIL PEPTIDASA | ⤷ Try a Trial |
China | 1216468 | ⤷ Try a Trial | |
China | 1530105 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NESINA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1084705 | C01084705/04 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 61893 08.03.2012 |
0896538 | 300280 | Netherlands | ⤷ Try a Trial | 300280, 20170424, EXPIRES: 20220320 |
1586571 | 172 5006-2014 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: EU/1/13/844/001 - EU/1/13/844/027 20130919 |
1174135 | C01174135/01 | Switzerland | ⤷ Try a Trial | FORMER REPRESENTATIVE: BOHEST AG, CH |
1084705 | SPC/GB14/084 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: LINAGLIPTIN; REGISTERED: UK EU/1/11/707/001-011 20110830 |
1084705 | CA 2014 00065 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LINAGLIPTIN; REG. NO/DATE: EU/1/11/707/001-011 20110824 |
1586571 | SPC/GB14/012 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/844/001-027 20130923 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |